Abstract:The emergence of multidrug-resistant bacteria has become a global crisis. Accumulating evidence shows that bacteriophages (phages) can rescue animals from a variety of lethal infections and be effective in treating drug-resistant infections in humans. Enterobacteriaceae, producing extended spectrum beta-lactamase enzymes (ESBLs), are resistant to a broad range of beta-lactamase antibiotics. One of the most common ESBL-producing gram-negative bacilli in Enterobacteriaceae is Escherichia coli. Since ESBL-producing E. coli poses a formidable challenge in the management of critically ill patients with bacterial infections, we undertook this study to explore the possible therapeutic utility of phages to control ESBL-producing E. coli infections. The phage Ø9882 used in this study was isolated from our hospital sewage and has lytic activity against a broad range of clinical isolates of ESBL-producing E. coli. ESBL-producing E. coli strains (n=30) were isolated in the clinic, and one of them was used to induce bacteremia in a murine model. Bacteremia was established by intraperitoneal (i.p.) injection of 3 x 10(7) CFU/ml, the minimum lethal dose (MLD) of bacterium in this animal model. Mice infected with the MLD of this strain alone died within 14 h, whereas a single i.p. inoculation of Ø9882 (MOI > or =10(-4)) given 40 min after the bacterial challenge led to 100% survival at 24-168 h, compared to 0% survival of saline-treated controls. Protection was obtained even when administration of the phage was delayed up to 60 min after the bacterial infection and the survival rate of infected animals was 60% at 168 h. Furthermore, it was shown that the therapeutic efficacy of Ø9882 in lethal systemic infection in our model is due to the functional capability of the phage and not the nonspecific immune effects. Our data both in vitro and in vivo revealed that: i) the protection of mice from death occurred only in animals infected with selected bacterial strains and the virulent phage specific to them; ii) when the phages were heat-inactivated, survival of the infected mice was strikingly decreased to 0; and iii) the level of antibody against the phage was not substantially elevated when the bacteremic animals were protected by the phage. The present findings indicate that phages can effectively rescue our mouse model from bacteremia and death, and thus provide the rationale and framework to evaluate the therapeutical efficacy of lytic phages against fatal ESBL-producing E. coli infections in humans.

In vivo activity of tedizolid phosphate injection

Comparative in vitro potency and kill curve activity of tedizolid and linezolid against Gram-positive bacteria isolated from Chinese hospitalized patients in 2013-2016.

In Vivo Activity of Doripenem in the Experimental Model of Mouse Septicemia Infected by Bacteria

In vivo antibacterial effect of cefathiamidine against mouse septicemia

In vivo activity of cefcapene proxetil in the experimental motel of mouse septicemia infected by bacteria

In Vitro Activities Of Tedizolid Compared With Other Antibiotics Against Gram-Positive Pathogens Associated With Hospital-Acquired Pneumonia, Skin And Soft Tissue Infection And Bloodstream Infection Collected From 26 Hospitals In China

Treatment effects of the combination of cefuroxime and tazobactam against mouse septicemia infected by β-lactamases producing strains

In Vitro Activities of Linezolid Against Clinical Isolates

Pharmacokinetics and Pharmacodynamics of a Novel Vancomycin Derivative LYSC98 in a Murine Thigh Infection Model Against Staphylococcus Aureus

Problematic Online Pornography Use: A Media Attendance Perspective

Establishment of the adenohypophyseal-testicular axis in the chick embryo. I. Testicular androgen levels.

In vivo activity of antibiotic 89-07 combined with flomoxef in the experimental therapy of mouse septicemia infected by mec A gene positive MRSA

Antibacterial Activities of Different Concentration Ratio of Cefotaxim-Sulbactam Against the Pathogenic Microorganisms

S1PR3 Agonist KRX-725 Promotes Bacterial Clearance and Affects the Outcome of Sepsis

Sensitivity analyses of linezolid against clinical gram-positive cocci isolates in vitro

Therapeutic effectiveness of bacteriophages in the rescue of mice with extended spectrum beta-lactamase-producing Escherichia coli bacteremia

Exploiting Organizational Models for Semantic Service Description,

In Vitro and In Vivo Antibacterial Activity, Toxicity and Resistance Analysis of Pleuromutilin Derivative Z33 against Methicillin-Resistant Staphylococcus aureus

Pharmacokinetic/pharmacodynamic analysis of tedizolid phosphate against Staphylococcus aureus and Streptococcus pneumoniae in children, adolescents, and adults by Monte Carlo simulation

Structural studies of P22 phage, precursor particles, and proteins by laser Raman spectroscopy.

Pharmacodynamic assessment of ertapenem (MK-0826) against Streptococcus pneumoniae in a murine neutropenic thigh infection model